Ergoteles LLC Argenx Se Transaction History

Ergoteles LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$343.2 - $395.75 $359,673 - $414,746	1,048 Added 101.26%	2,083 $735,000
Q2 2022 Aug 12, 2022	BUY	$269.58 - $378.88 $279,015 - $392,140	1,035 New	1,035 $392,000
Q1 2022 May 13, 2022	SELL	$254.45 - $351.06 $490,579 - $676,843	-1,928 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$272.01 - $353.03 $524,435 - $680,641	1,928 New	1,928 $675,000
Q3 2021 Nov 15, 2021	SELL	$295.0 - $350.58 $315,945 - $375,471	-1,071 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$257.11 - $319.92 $275,364 - $342,634	1,071 New	1,071 $322,000

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $34.8B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Ergoteles LLC, based on Form 13F filings with the SEC.

Stay updated on Ergoteles LLC with notifications on news.